Skip to main content
. 1998 Aug;113(2):244–251. doi: 10.1046/j.1365-2249.1998.00665.x

Fig. 2.

Fig. 2

The difference in peripheral blood mononuclear cell (PBMC) response to recombinant hepatitis B virus (HBV) core protein (rHBc) in patients with HLA-DR13 compared with patients without HLA-DR13 is maintained throughout the observation period. The median Δct/min of patients with HLA-DR13 (▪) and of patients without HLA-DR13 (□) have been calculated for the first 2 weeks, weeks 3 and 4, weeks 5 and 6 and during follow up. The numbers on the bars represent the number of assays during that time period.